Immunogenicity and safety of lyophilized and liquid dengue tetravalent vaccine candidate formulations in healthy adults: a randomized, phase 2 clinical trial

Immunogenicity and safety of lyophilized and liquid dengue tetravalent vaccine candidate formulations in healthy adults: a randomized, phase 2 clinical trial

Takeda has developed a live-attenuated dengue tetravalent vaccine candidate (TAK-003) which has been shown to be immunogenic with acceptable reactogenicity in phase 1 trials. In agreement with World Health Organization prequalification requirements for dengue vaccines, Takeda has manufactured a lyop...

Full description

Bibliographic Details
Main Authors: Mark Turner, Athanasia Papadimitriou, Peter Winkle, Nathan Segall, Michael Levin, Matthew Doust, Casey Johnson, Gregg Lucksinger, Carlos Fierro, Paul Pickrell, Marsha Raanan, Vianney Tricou, Astrid Borkowski, Derek Wallace
Format: Article
Language:English
Published: Taylor & Francis Group 2020-10-01
Series:Human Vaccines & Immunotherapeutics
Subjects:
dengue
vaccine
adults
tetravalent
takeda
Online Access:http://dx.doi.org/10.1080/21645515.2020.1727697

Internet

http://dx.doi.org/10.1080/21645515.2020.1727697

Similar Items